Document is current

Any future updates will be listed below

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

Crossref DOI link: https://doi.org/10.1038/s43856-026-01483-z

Published Online: 2026-03-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark